respiratory syncytial virus

News

Sanofi sets out plan to lead the RSV vaccine market

Sanofi is trailing behind GSK and Pfizer when it comes to vaccines for respiratory syncytial virus (RSV), but it still thinks it can be the top player in the market with a

News

CDC panel backs use of GSK, Pfizer’s RSV shots this year

Adults aged 60 and over in the US will be eligible for vaccinations with respiratory syncytial virus (RSV) vaccines from GSK or Pfizer later this year, if the Centers for

News

FDA advisors back Beyfortus for RSV prevention

An FDA advisory committee has voted in favour of approving AstraZeneca and Sanofi’s one-shot antibody treatment to prevent respiratory syncytial virus (RSV) disease in inf

News

GSK claims first EU approval for an RSV vaccine

GSK’s Arexvy has become the first vaccine for respiratory syncytial virus (RSV) to be approved in the EU, getting the nod from the European Commission for use in older adu

News

After FDA nod, Pfizer joins GSK in RSV vaccine market

The FDA has approved Pfizer’s respiratory syncytial virus (RSV) vaccine for older adults, just a few weeks after a rival shot from GSK became the first to be cleared in th

News

FDA advisors back Pfizer’s RSV shot for maternal use

An FDA advisory committee has endorsed Pfizer’s respiratory syncytial virus (RSV) vaccine for use in expectant mothers, potentially opening up a niche for the shot, where

Sanofi sets out plan to lead the RSV vaccine market

CDC panel backs use of GSK, Pfizer’s RSV shots this year

FDA advisors back Beyfortus for RSV prevention

GSK claims first EU approval for an RSV vaccine

After FDA nod, Pfizer joins GSK in RSV vaccine market

FDA advisors back Pfizer’s RSV shot for maternal use

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

respiratory syncytial virus

Editor's Picks